nach oben

Clinical Reviews in Allergy & Immunology

Erschienen in:

31.10.2017

Cutaneous Manifestations of Dermatomyositis: a Comprehensive Review

verfasst von: Carlo Mainetti, Benedetta Terziroli Beretta-Piccoli, Carlo Selmi

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Dermatomyositis (DM) is an idiopathic inflammatory myopathy characterized by the presence of skin lesions and inflammation of skeletal muscles; however, this feature may be absent in amyopathic DM. DM is a rare disease, occurring at any age, and has two peaks of incidence: one in childhood between 5 and 15 years of age and one in adulthood between 40 and 60 years, with a female preponderance. DM has been associated with malignancy; therefore, every newly diagnosed patient should undergo screening investigations, but evidence-based guidelines on their extension are lacking. The etiopathogenesis is still unclear, but a range of factors such as genetic predisposition, environment triggers, and immune- and non-immune-mediated mechanisms play a role in the development of the disorder. Some dermatological findings and new discoveries on immunological mechanisms in DM, including the association of certain autoantibodies with cancer, can be helpful in clinical practice. Therapy should consider both skin and muscle or internal organ involvement. Photoprotection, including the use of antimalarial drugs, plays an important role in the therapeutic approach of skin involvement. Treatment of muscle and internal organ involvement is based on systemic corticosteroids, alone or in association with disease-modifying antirheumatic drugs. Intravenous immunoglobulins have been demonstrated to be effective as second-line therapy. Rituximab is an emerging treatment for difficult-to-treat DM, both in adults and children. In this review article, we discuss DM subforms, focusing on their dermatological manifestations that can be classified as pathognomonic, characteristic, compatible, less common, rare, recently-described, and non-specific skin lesions.

Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347. https://doi.org/10.1056/NEJM197502132920706 PubMedCrossRef

Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403–407. https://doi.org/10.1056/NEJM197502202920807 PubMedCrossRef

Hoogendijk JE, Amato AA, Lecky BR et al (2004) 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord NMD 14:337–345. https://doi.org/10.1016/j.nmd.2004.02.006 PubMedCrossRef

Troyanov Y, Targoff IN, Tremblay J-L et al (2005) Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 84:231–249CrossRef

Casciola-Rosen L, Rosen A (2014) Chapter 39—the autoimmune myopathies. In: Autoimmune Dis, 5th edn. Academic Press, Boston, pp 547–554CrossRef

Troyanov Y, Targoff IN, Payette M-P et al (2014) Redefining dermatomyositis: a description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features. Medicine (Baltimore) 93:318–332. https://doi.org/10.1097/MD.0000000000000222 CrossRef

Cavazzana I, Fredi M, Selmi C et al (2017) The clinical and histological spectrum of idiopathic inflammatory myopathies. Clin Rev Allergy Immunol 52:88–98. https://doi.org/10.1007/s12016-015-8517-4 PubMedCrossRef

Iaccarino L, Ghirardello A, Bettio S et al (2014) The clinical features, diagnosis and classification of dermatomyositis. J Autoimmun 48–49:122–127. https://doi.org/10.1016/j.jaut.2013.11.005 PubMedCrossRef

Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362:971–982. https://doi.org/10.1016/S0140-6736(03)14368-1 PubMedCrossRef

10.

Rider LG, Katz JD, Jones OY (2013) Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin N Am 39:877–904. https://doi.org/10.1016/j.rdc.2013.06.001 CrossRef

11.

Rider LG, Shah M, Mamyrova G et al (2013) The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 92:223–243. https://doi.org/10.1097/MD.0b013e31829d08f9 CrossRef

12.

Venalis P, Lundberg IE (2014) Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy. Rheumatology Oxford 53:397–405. https://doi.org/10.1093/rheumatology/ket279 PubMedCrossRef

13.

van der Kooi AJ, de Visser M (2014) Idiopathic inflammatory myopathies. Handb Clin Neurol 119:495–512. https://doi.org/10.1016/B978-0-7020-4086-3.00032-1 PubMedCrossRef

14.

Prieto S, Grau JM (2010) The geoepidemiology of autoimmune muscle disease. Autoimmun Rev 9:A330–A334. https://doi.org/10.1016/j.autrev.2009.11.006 PubMedCrossRef

15.

Oddis CV, Conte CG, Steen VD, Medsger TA (1990) Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol 17:1329–1334PubMed

16.

Pachman LM, Hayford JR, Chung A et al (1998) Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol 25:1198–1204PubMed

17.

Mastaglia FL, Phillips BA (2002) Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum Dis Clin N Am 28:723–741CrossRef

18.

Furst DE, Amato AA, Iorga ŞR et al (2012) Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve 45:676–683. https://doi.org/10.1002/mus.23302 PubMedCrossRef

19.

Tan JA, Roberts-Thomson PJ, Blumbergs P et al (2013) Incidence and prevalence of idiopathic inflammatory myopathies in South Australia: a 30-year epidemiologic study of histology-proven cases. Int J Rheum Dis 16:331–338. https://doi.org/10.1111/j.1756-185X.2011.01669.x PubMedCrossRef

20.

Rosa J, Garrot LF, Navarta DA et al (2013) Incidence and prevalence of polymyositis and dermatomyositis in a health management organization in Buenos Aires. J Clin Rheumatol 19:303–307. https://doi.org/10.1097/RHU.0b013e3182a21ba8 PubMedCrossRef

21.

Bendewald MJ, Wetter DA, Li X, Davis MDP (2010) Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol 146:26–30. https://doi.org/10.1001/archdermatol.2009.328 PubMedCrossRef

22.

Ramanan AV, Feldman BM (2002) Clinical outcomes in juvenile dermatomyositis. Curr Opin Rheumatol 14:658–662PubMedCrossRef

23.

Okada S, Weatherhead E, Targoff IN et al (2003) Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum 48:2285–2293. https://doi.org/10.1002/art.11090 PubMedCrossRef

24.

Shah M, Targoff IN, Rice MM et al (2013) Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis. Arthritis Rheum 65:1934–1941. https://doi.org/10.1002/art.37985 PubMedPubMedCentralCrossRef

25.

Christensen ML, Pachman LM, Schneiderman R et al (1986) Prevalence of coxsackie B virus antibodies in patients with juvenile dermatomyositis. Arthritis Rheum 29:1365–1370PubMedCrossRef

26.

Chevrel G, Page G, Granet C et al (2003) Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol 137:125–133PubMedCrossRef

27.

Page G, Sattler A, Kersten S et al (2004) Plasma cell-like morphology of Th1-cytokine-producing cells associated with the loss of CD3 expression. Am J Pathol 164:409–417. https://doi.org/10.1016/S0002-9440(10)63131-8 PubMedPubMedCentralCrossRef

28.

Waschbisch A, Schwab N, Ruck T et al (2010) FOXP3+ T regulatory cells in idiopathic inflammatory myopathies. J Neuroimmunol 225:137–142. https://doi.org/10.1016/j.jneuroim.2010.03.013 PubMedCrossRef

29.

Banica L, Besliu A, Pistol G et al (2009) Quantification and molecular characterization of regulatory T cells in connective tissue diseases. Autoimmunity 42:41–49. https://doi.org/10.1080/08916930802282651 PubMedCrossRef

30.

Thompson C, Piguet V, Choy E (2017) The pathogenesis of dermatomyositis. Br J Dermatol. https://doi.org/10.1111/bjd.15607

31.

Horowitz HW, Sanghera K, Goldberg N et al (1994) Dermatomyositis associated with Lyme disease: case report and review of Lyme myositis. Clin Infect Dis 18:166–171PubMedCrossRef

32.

Satoh M, Tanaka S, Ceribelli A et al (2017) A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 52:1–19. https://doi.org/10.1007/s12016-015-8510-y PubMedCrossRef

33.

Levine TD (2005) Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52:601–607. https://doi.org/10.1002/art.20849 PubMedCrossRef

34.

Rios Fernández R, Callejas Rubio J-L, Sánchez Cano D et al (2009) Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin Exp Rheumatol 27:1009–1016PubMed

35.

Zong M, Lundberg IE (2011) Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol 7:297–306. https://doi.org/10.1038/nrrheum.2011.39 PubMedCrossRef

36.

Shovman O, Agmon-Levin N, Gilburd B et al (2015) A fully automated IIF system for the detection of antinuclear antibodies and antineutrophil cytoplasmic antibodies. Immunol Res 61:135–140. https://doi.org/10.1007/s12026-014-8588-y PubMedCrossRef

37.

Stanford SM, Bottini N (2014) PTPN22: the archetypal non-HLA autoimmunity gene. Nat Rev Rheumatol 10:602–611. https://doi.org/10.1038/nrrheum.2014.109 PubMedPubMedCentralCrossRef

38.

Rider LG, Artlett CM, Foster CB et al (2000) Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies. Clin Exp Immunol 121:47–52PubMedPubMedCentralCrossRef

39.

Moghadam-Kia S, Oddis CV, Aggarwal R (2017) Modern therapies for idiopathic inflammatory myopathies (IIMs): role of biologics. Clin Rev Allergy Immunol 52:81–87. https://doi.org/10.1007/s12016-016-8530-2 PubMedPubMedCentralCrossRef

40.

Francès C (2007) Dermatomyosite. In: Bessis D, Francès C, Guillot B, Guilhou J-J (eds) Manif. Dermatol. Connect. Vasc. Affect. Systémiques Apparent. Dermatol. Médecine. Springer Paris, Paris, pp 69–83

41.

Callen JP (2010) Cutaneous manifestations of dermatomyositis and their management. Curr Rheumatol Rep 12:192–197. https://doi.org/10.1007/s11926-010-0100-7

42.

Muro Y, Sugiura K, Akiyama M (2016) Cutaneous manifestations in dermatomyositis: key clinical and serological features—a comprehensive review. Clin Rev Allergy Immunol 51:293–302. https://doi.org/10.1007/s12016-015-8496-5 PubMedCrossRef

43.

Vleugels RA, Callen JP (2017) Dermatomyositis. In: Callen JP, Jorizzo JL, Zone JJ et al (eds) Dermatological signs of systemic disease. Elsevier Edinburg, London, New York, Oxford, Philadelphia, St Louis, Sydney, Toronto, pp 13–21

44.

Sontheimer RD (2002) Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin 20:387–408PubMedCrossRef

45.

Santmyire-Rosenberger B, Dugan EM (2003) Skin involvement in dermatomyositis. Curr Opin Rheumatol 15:714–722PubMedCrossRef

46.

Balin SJ, Wetter DA, Andersen LK, Davis MDP (2012) Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996-2009. Arch Dermatol 148:455–462. https://doi.org/10.1001/archdermatol.2011.2052 PubMedCrossRef

47.

Hansen CB, Callen JP (2010) Connective tissue panniculitis: lupus panniculitis, dermatomyositis, morphea/scleroderma. Dermatol Ther 23:341–349. https://doi.org/10.1111/j.1529-8019.2010.01334.x PubMedCrossRef

48.

Valenzuela A, Chung L, Casciola-Rosen L, Fiorentino D (2014) Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. JAMA Dermatol 150:724–729. https://doi.org/10.1001/jamadermatol.2013.10416 PubMedPubMedCentralCrossRef

49.

Cavagna L, Nuño L, Scirè CA et al (2017) Serum Jo-1 autoantibody and isolated arthritis in the antisynthetase syndrome: review of the literature and report of the experience of AENEAS collaborative group. Clin Rev Allergy Immunol 52:71–80. https://doi.org/10.1007/s12016-016-8528-9 PubMedCrossRef

50.

Jara M, Amérigo J, Duce S, Borbujo J (1996) Dermatomyositis and flagellate erythema. Clin Exp Dermatol 21:440–441PubMedCrossRef

51.

Solans R, Cortés J, Selva A et al (2002) Panniculitis: a cutaneous manifestation of dermatomyositis. J Am Acad Dermatol 46:S148–S150PubMedCrossRef

52.

Márton K, Hermann P, Dankó K et al (2005) Evaluation of oral manifestations and masticatory force in patients with polymyositis and dermatomyositis. J Oral Pathol Med 34:164–169. https://doi.org/10.1111/j.1600-0714.2004.00280.x PubMedCrossRef

53.

Gonçalves LM, Bezerra-Júnior JRS, Gordón-Núñez MA et al (2011) Oral manifestations as important symptoms for juvenile dermatomyositis early diagnosis: a case report. Int J Paediatr Dent 21:77–80. https://doi.org/10.1111/j.1365-263X.2010.01074.x PubMedCrossRef

54.

Ghali FE, Stein LD, Fine JD et al (1999) Gingival telangiectases: an underappreciated physical sign of juvenile dermatomyositis. Arch Dermatol 135:1370–1374PubMedCrossRef

55.

Ward I, Hiles P, Arroyo R et al (2016) Digital pulp ulcerations and inverse Gottron papules in melanoma differentiation-associated gene 5-related dermatomyositis. J Clin Rheumatol 22:274–275. https://doi.org/10.1097/RHU.0000000000000377 PubMedCrossRef

56.

Quinter SD, Chiu YE, Lyon VB et al (2012) Inverse Gottron’s papules: an unusual cutaneous manifestation of juvenile dermatomyositis. Pediatr Dermatol 29:641–644. https://doi.org/10.1111/j.1525-1470.2011.01585.x PubMedCrossRef

57.

Fiorentino D, Chung L, Zwerner J et al (2011) The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 65:25–34. https://doi.org/10.1016/j.jaad.2010.09.016 PubMedPubMedCentralCrossRef

58.

Narang NS, Casciola-Rosen L, Li S et al (2015) Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease. Arthritis Care Res 67:667–672. https://doi.org/10.1002/acr.22498 CrossRef

59.

Nagashima T, Nakamura J, Iwamoto M, Minota S (2017) Deep cutaneous ulcers in dermatomyositis. Intern Med 56:1749–1750. https://doi.org/10.2169/internalmedicine.56.8343 PubMedPubMedCentralCrossRef

60.

Girard C, Vincent T, Bessis D (2013) Dermatomyositis and acute interstitial lung disease associated with MDA-5 antibodies: an atypical case. Ann Dermatol Venereol 140:628–634. https://doi.org/10.1016/j.annder.2013.04.083 PubMedCrossRef

61.

Cox JT, Gullotti DM, Mecoli CA et al (2017) “Hiker’s feet”: a novel cutaneous finding in the inflammatory myopathies. Clin Rheumatol 36:1683–1686. https://doi.org/10.1007/s10067-017-3598-5 PubMedCrossRef

62.

Cheong WK, Hughes GR, Norris PG, Hawk JL (1994) Cutaneous photosensitivity in dermatomyositis. Br J Dermatol 131:205–208PubMedCrossRef

63.

Vleugels RA, Callen JP (2014) Dermatomyositis. In: Lebwohl MG, Berth-Jones J, Heymann WR et al (eds) Treatment of skin disease. Comprehensive therapeutic strategies. Elsevier Saunders, pp 183–187

64.

Dourmishev LA, Wollina U (2006) Dermatomyositis: immunopathologic study of skin lesions. Acta Dermatovenerol Alp Pannonica Adriat 15:45–51PubMed

65.

Hoeltzel MF, Oberle EJ, Robinson AB et al (2014) The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis. Curr Rheumatol Rep 16:467. https://doi.org/10.1007/s11926-014-0467-y PubMedPubMedCentralCrossRef

66.

Morel Ayala Z, Martínez Ramírez R, Mendieta Zerón S et al (2008) Juvenile dermatomyositis and extensive calcinosis. Treatment with methylprednisolone and methotrexate. Reumatol Clin 4:248–250. https://doi.org/10.1016/S1699-258X(08)75546-3 PubMedCrossRef

67.

Lie JT (1995) Cardiac manifestations in polymyositis/dermatomyositis: how to get to heart of the matter. J Rheumatol 22:809–811PubMed

68.

Gonzalez-Lopez L, Gamez-Nava JI, Sanchez L et al (1996) Cardiac manifestations in dermato-polymyositis. Clin Exp Rheumatol 14:373–379PubMed

69.

Denbow CE, Lie JT, Tancredi RG, Bunch TW (1979) Cardiac involvement in polymyositis: a clinicopathologic study of 20 autopsied patients. Arthritis Rheum 22:1088–1092PubMedCrossRef

70.

Riemekasten G, Opitz C, Audring H et al (1999) Beware of the heart: the multiple picture of cardiac involvement in myositis. Rheumatology Oxford 38:1153–1157PubMedCrossRef

71.

Gottdiener JS, Sherber HS, Hawley RJ, Engel WK (1978) Cardiac manifestations in polymyositis. Am J Cardiol 41:1141–1149PubMedCrossRef

72.

Lega J-C, Reynaud Q, Belot A et al (2015) Idiopathic inflammatory myopathies and the lung. Eur Respir Rev 24:216–238. https://doi.org/10.1183/16000617.00002015 PubMedCrossRef

73.

Cottin V, Thivolet-Béjui F, Reynaud-Gaubert M et al (2003) Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 22:245–250PubMedCrossRef

74.

Lega J-C, Fabien N, Reynaud Q et al (2014) The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev 13:883–891. https://doi.org/10.1016/j.autrev.2014.03.004 PubMedCrossRef

75.

Hayashi S, Tanaka M, Kobayashi H et al (2008) High-resolution computed tomography characterization of interstitial lung diseases in polymyositis/dermatomyositis. J Rheumatol 35:260–269PubMed

76.

Mugii N, Hasegawa M, Matsushita T et al (2016) Oropharyngeal dysphagia in dermatomyositis: associations with clinical and laboratory features including autoantibodies. PLoS One 11:e0154746. https://doi.org/10.1371/journal.pone.0154746 PubMedPubMedCentralCrossRef

77.

McCann LJ, Garay SM, Ryan MM et al (2007) Oropharyngeal dysphagia in juvenile dermatomyositis (JDM): an evaluation of videofluoroscopy swallow study (VFSS) changes in relation to clinical symptoms and objective muscle scores. Rheumatology Oxford 46:1363–1366. https://doi.org/10.1093/rheumatology/kem131 PubMedCrossRef

78.

Pagnini I, Vitale A, Selmi C et al (2017) Idiopathic inflammatory myopathies: an update on classification and treatment with special focus on juvenile forms. Clin Rev Allergy Immunol 52:34–44. https://doi.org/10.1007/s12016-015-8512-9 PubMedCrossRef

79.

Kronbichler A, Mayer G (2013) Renal involvement in autoimmune connective tissue diseases. BMC Med 11:95. https://doi.org/10.1186/1741-7015-11-95 PubMedPubMedCentralCrossRef

80.

Regan M, Haque U, Pomper M et al (2001) Central nervous system vasculitis as a complication of refractory dermatomyositis. J Rheumatol 28:207–211PubMed

81.

Jimenez C, Rowe PC, Keene D (1994) Cardiac and central nervous system vasculitis in a child with dermatomyositis. J Child Neurol 9:297–300. https://doi.org/10.1177/088307389400900315 PubMedCrossRef

82.

Missumi LS, de Souza FHC, Andrade JQ, Shinjo SK (2015) Pregnancy outcomes in dermatomyositis and polymyositis patients. Rev Bras Reumatol 55:95–102. https://doi.org/10.1016/j.rbr.2014.10.001 PubMedCrossRef

83.

Pinal-Fernandez I, Selva-O’Callaghan A, Fernandez-Codina A et al (2014) “Pregnancy in adult-onset idiopathic inflammatory myopathy”: report from a cohort of myositis patients from a single center. Semin Arthritis Rheum 44:234–240. https://doi.org/10.1016/j.semarthrit.2014.05.004 PubMedCrossRef

84.

Chen JS, Roberts CL, Simpson JM, March LM (2015) Pregnancy outcomes in women with rare autoimmune diseases. Arthritis Rheumatol 67:3314–3323. https://doi.org/10.1002/art.39311 PubMedCrossRef

85.

Beretta-Piccoli BT, Mieli-Vergani G, Vergani D (2017) Autoimmune hepatitis: standard treatment and systematic review of alternative treatments. World J Gastroenterol 23:6030–6048. https://doi.org/10.3748/wjg.v23.i33.6030 CrossRef

86.

Ochiai M, Sato E, Tanaka E et al (2017) Successful delivery in a patient with clinically amyopathic dermatomyositis during pregnancy despite first-trimester acute exacerbation of interstitial lung disease. Mod Rheumatol 27:364–368. https://doi.org/10.3109/14397595.2014.975906 PubMedCrossRef

87.

Morihara K, Katoh N, Hirano S, Kishimoto S (2004) Amyopathic dermatomyositis presenting during pregnancy. J Am Acad Dermatol 51:838–840. https://doi.org/10.1016/j.jaad.2004.05.024 PubMedCrossRef

88.

Euwer RL, Sontheimer RD (1991) Amyopathic dermatomyositis (dermatomyositis siné myositis). Presentation of six new cases and review of the literature. J Am Acad Dermatol 24:959–966PubMedCrossRef

89.

Pearson CM, Bohan A (1977) The spectrum of polymyositis and dermatomyositis. Med Clin North Am 61:439–457PubMedCrossRef

90.

Ghazi E, Sontheimer RD, Werth VP (2013) The importance of including amyopathic dermatomyositis in the idiopathic inflammatory myositis spectrum. Clin Exp Rheumatol 31:128–134PubMed

91.

Morganroth PA, Kreider ME, Okawa J et al (2010) Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations. Arch Dermatol 146:729–738. https://doi.org/10.1001/archdermatol.2010.134 PubMedPubMedCentralCrossRef

92.

Gerami P, Schope JM, McDonald L et al (2006) A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 54:597–613. https://doi.org/10.1016/j.jaad.2005.10.041 PubMedCrossRef

93.

Sontheimer RD (2002) Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46:626–636PubMedCrossRef

94.

Barnes BE, Mawr B (1976) Dermatomyositis and malignancy. A review of the literature. Ann Intern Med 84:68–76PubMedCrossRef

95.

Chow WH, Gridley G, Mellemkjaer L et al (1995) Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control CCC 6:9–13PubMedCrossRef

96.

Buchbinder R, Forbes A, Hall S et al (2001) Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 134:1087–1095PubMedCrossRef

97.

Chen D, Yuan S, Wu X et al (2014) Incidence and predictive factors for malignancies with dermatomyositis: a cohort from southern China. Clin Exp Rheumatol 32:615–621PubMed

98.

Stockton D, Doherty VR, Brewster DH (2001) Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 85:41–45. https://doi.org/10.1054/bjoc.2001.1699 PubMedPubMedCentralCrossRef

99.

Sigurgeirsson B, Lindelöf B, Edhag O, Allander E (1992) Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 326:363–367. https://doi.org/10.1056/NEJM199202063260602 PubMedCrossRef

100.

Olazagasti JM, Baez PJ, Wetter DA, Ernste FC (2015) Cancer risk in dermatomyositis: a meta-analysis of cohort studies. Am J Clin Dermatol 16:89–98. https://doi.org/10.1007/s40257-015-0120-1 PubMedCrossRef

101.

Kuo C-F, See L-C, K-H Y et al (2011) Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br J Dermatol 165:1273–1279. https://doi.org/10.1111/j.1365-2133.2011.10595.x PubMedCrossRef

102.

Azuma K, Yamada H, Ohkubo M et al (2011) Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis. Mod Rheumatol 21:178–183. https://doi.org/10.1007/s10165-010-0362-y PubMedCrossRef

103.

Mannion ML, Beukelman T (2013) What is the background incidence of malignancy in children with rheumatic disease? Curr Rheumatol Rep 15:310. https://doi.org/10.1007/s11926-012-0310-2 PubMedCrossRef

104.

Morris P, Dare J (2010) Juvenile dermatomyositis as a paraneoplastic phenomenon: an update. J Pediatr Hematol Oncol 32:189–191. https://doi.org/10.1097/MPH.0b013e3181bf29a2 PubMedCrossRef

105.

Lu X, Yang H, Shu X et al (2014) Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis. PLoS One 9:e94128. https://doi.org/10.1371/journal.pone.0094128 PubMedPubMedCentralCrossRef

106.

Requena C, Alfaro A, Traves V et al (2014) Paraneoplastic dermatomyositis: a study of 12 cases. Actas Dermosifiliogr 105:675–682. https://doi.org/10.1016/j.ad.2013.11.007 PubMedCrossRef

107.

Amoura Z, Duhaut P, Huong DLT et al (2005) Tumor antigen markers for the detection of solid cancers in inflammatory myopathies. Cancer Epidemiol Biomark Prev 14:1279–1282. https://doi.org/10.1158/1055-9965.EPI-04-0624 CrossRef

108.

Sunderkötter C, Nast A, Worm M et al (2016) Guidelines on dermatomyositis—excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG 14:321–338. https://doi.org/10.1111/ddg.12909 CrossRef

109.

Quain RD, Werth VP (2006) Management of cutaneous dermatomyositis: current therapeutic options. Am J Clin Dermatol 7:341–351PubMedCrossRef

110.

Woo TY, Callen JP, Voorhees JJ et al (1984) Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol 10:592–600. https://doi.org/10.1016/S0190-9622(84)80263-7 PubMedCrossRef

111.

Ang GC, Werth VP (2005) Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. Arch Dermatol 141:855–859. https://doi.org/10.1001/archderm.141.7.855 PubMedCrossRef

112.

Mittal L, Werth VP (2017) The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis. J Am Acad Dermatol 77:374–377. https://doi.org/10.1016/j.jaad.2017.03.027 PubMedCrossRef

113.

Hollar CB, Jorizzo JL (2004) Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J Dermatol Treat 15:35–39. https://doi.org/10.1080/09541440042000269 CrossRef

114.

Dalakas MC, Illa I, Dambrosia JM et al (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993–2000. https://doi.org/10.1056/NEJM199312303292704 PubMedCrossRef

115.

Dalakas MC (1998) Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Neurology 51:S37–S45PubMedCrossRef

116.

Lam CG, Manlhiot C, Pullenayegum EM, Feldman BM (2011) Efficacy of intravenous Ig therapy in juvenile dermatomyositis. Ann Rheum Dis 70:2089–2094. https://doi.org/10.1136/ard.2011.153718 PubMedCrossRef

117.

Dourmishev LA, Guleva DV, Miteva LG (2017) Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology. Wien Med Wochenschr 1946. https://doi.org/10.1007/s10354-017-0595-x

118.

Klein-Gitelman MS, Waters T, Pachman LM (2000) The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis. Arthritis Care Res 13:360–368PubMedCrossRef

119.

Postolova A, Chen JK, Chung L (2016) Corticosteroids in myositis and scleroderma. Rheum Dis Clin N Am 42:103–118, ix. https://doi.org/10.1016/j.rdc.2015.08.011 CrossRef

120.

Griger Z, Nagy-Vincze M, Dankó K (2017) Pharmacological management of dermatomyositis. Expert Rev Clin Pharmacol:1–10. https://doi.org/10.1080/17512433.2017.1353910

121.

Bolosiu HD, Man L, Rednic S (1999) The effect of methylprednisolone pulse therapy in polymyositis/dermatomyositis. Adv Exp Med Biol 455:349–357PubMedCrossRef

122.

Drake LA, Dinehart SM, Farmer ER et al (1996) Guidelines of care for dermatomyositis. American Academy of Dermatology. J Am Acad Dermatol 34:824–829PubMedCrossRef

123.

Ruperto N, Pistorio A, Oliveira S et al (2016) Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet 387:671–678. https://doi.org/10.1016/S0140-6736(15)01021-1 PubMedCrossRef

124.

Joffe MM, Love LA, Leff RL et al (1993) Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 94:379–387PubMedCrossRef

125.

Click JW, Qureshi AA, Vleugels RA (2013) Methotrexate for the treatment of cutaneous dermatomyositis. J Am Acad Dermatol 68:1043–1045. https://doi.org/10.1016/j.jaad.2013.01.008 PubMedCrossRef

126.

Schiopu E, Phillips K, MacDonald PM et al (2012) Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther 14:R22. https://doi.org/10.1186/ar3704 PubMedPubMedCentralCrossRef

127.

Morganroth PA, Kreider ME, Werth VP (2010) Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res 62:1496–1501. https://doi.org/10.1002/acr.20212 CrossRef

128.

Rouster-Stevens KA, Morgan GA, Wang D, Pachman LM (2010) Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res 62:1446–1451. https://doi.org/10.1002/acr.20269 CrossRef

129.

Cozzani E, Cinotti E, Felletti R et al (2013) Amyopathic dermatomyositis with lung involvement responsive to mycophenolate mofetil. Immunopharmacol Immunotoxicol 35:687–692. https://doi.org/10.3109/08923973.2013.833624 PubMedCrossRef

130.

Ueno K-I, Shimojima Y, Kishida D et al (2016) Advantage of administering tacrolimus for improving prognosis of patients with polymyositis and dermatomyositis. Int J Rheum Dis 19:1322–1330. https://doi.org/10.1111/1756-185X.12931 PubMedCrossRef

131.

Chighizola CB, Ong VH, Meroni PL (2017) The use of cyclosporine a in rheumatology: a 2016 comprehensive review. Clin Rev Allergy Immunol 52:401–423. https://doi.org/10.1007/s12016-016-8582-3 PubMedCrossRef

132.

Nagappa M, Taly AB, Sinha S et al (2013) Efficacy and limitations of pulse cyclophosphamide therapy in polymyositis and dermatomyositis. J Clin Neuromuscul Dis 14:161–168. https://doi.org/10.1097/CND.0b013e31828ee913 PubMedCrossRef

133.

Chung L, Genovese MC, Fiorentino DF (2007) A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 143:763–767. https://doi.org/10.1001/archderm.143.6.763 PubMedCrossRef

134.

Mahler EAM, Blom M, Voermans NC et al (2011) Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology Oxford 50:2206–2213. https://doi.org/10.1093/rheumatology/ker088 PubMedCrossRef

135.

Oddis CV, Reed AM, Aggarwal R et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65:314–324. https://doi.org/10.1002/art.37754 PubMedPubMedCentralCrossRef

136.

Muscle Study Group (2011) A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 70:427–436. https://doi.org/10.1002/ana.22477 CrossRef

137.

Conway R, Low C, Coughlan RJ et al (2015) Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials. BMJ 350:h1269PubMedPubMedCentralCrossRef

138.

Fisler RE, Liang MG, Fuhlbrigge RC et al (2002) Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 47:505–511PubMedCrossRef

139.

Fredi M, Bartoli F, Cavazzana I et al (2017) Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options. Clin Exp Rheumatol 35:303–308PubMed

140.

Enders FB, Bader-Meunier B, Baildam E et al (2017) Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis 76:329–340. https://doi.org/10.1136/annrheumdis-2016-209247 PubMedCrossRef

141.

Ruck T, Bittner S, Kuhlmann T et al (2015) Long-term efficacy of alemtuzumab in polymyositis. Rheumatology Oxford 54:560–562. https://doi.org/10.1093/rheumatology/keu484 PubMedCrossRef

142.

Thompson B, Corris P, Miller JAL et al (2008) Alemtuzumab (Campath-1H) for treatment of refractory polymyositis. J Rheumatol 35:2080–2082PubMedCrossRef

143.

Arabshahi B, Silverman RA, Jones OY, Rider LG (2012) Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr 160:520–522. https://doi.org/10.1016/j.jpeds.2011.11.057 PubMedPubMedCentralCrossRef

144.

Higgs BW, Zhu W, Morehouse C et al (2014) A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 73:256–262. https://doi.org/10.1136/annrheumdis-2012-202794 PubMedCrossRef

145.

Guo X, Higgs BW, Rebelatto M et al (2014) Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis. Rheumatology Oxford 53:686–695. https://doi.org/10.1093/rheumatology/ket413 PubMedCrossRef

146.

Wang D, Zhang H, Cao M et al (2011) Efficacy of allogeneic mesenchymal stem cell transplantation in patients with drug-resistant polymyositis and dermatomyositis. Ann Rheum Dis 70:1285–1288. https://doi.org/10.1136/ard.2010.141804 PubMedCrossRef

147.

Choudhary MM, Hajj-Ali RA, Lowder CY (2014) Gender and ocular manifestations of connective tissue diseases and systemic vasculitides J Ophthalmol 2014:403042. https://doi.org/10.1155/2014/403042

Titel: Cutaneous Manifestations of Dermatomyositis: a Comprehensive Review
verfasst von: Carlo Mainetti
Benedetta Terziroli Beretta-Piccoli
Carlo Selmi
Publikationsdatum: 31.10.2017
Verlag: Springer US
Erschienen in: Clinical Reviews in Allergy & Immunology / Ausgabe 3/2017
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-017-8652-1

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Cutaneous Manifestations of Dermatomyositis: a Comprehensive Review

Abstract

Neu im Fachgebiet HNO

Akuter Schwindel: Wann lohnt sich eine MRT?

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Update HNO

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2017

Cutaneous Manifestations of Medium- and Large-Vessel Vasculitis

Neonatal Systemic Lupus Erythematosus Syndrome: a Comprehensive Review

Cutaneous and Mucosal Manifestations of Sjögren’s Syndrome

Cutaneous Manifestations of Small-Vessel Leukocytoclastic Vasculitides in Childhood

Cutaneous Manifestations of ANCA-Associated Small Vessels Vasculitis

Skin Manifestations Associated with Autoimmune Liver Diseases: a Systematic Review

Neu im Fachgebiet HNO

Akuter Schwindel: Wann lohnt sich eine MRT?

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Update HNO